Breaks Categories: News

WednesdayNov 13, 2024 10:17 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports Q3 2024 Results and Progress on ALS Treatment Pathway

Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for accelerated approval of CNM-Au8 for ALS, a 1-for-20 reverse stock split to meet Nasdaq requirements, an amended debt facility extending funding into Q2 2025, and a $7.3 million funding round. Clene’s Phase 3 RESTORE-ALS trial was presented in October, showcasing the company's commitment to ALS treatment innovation. Financially, Clene ended Q3 with $14.6 million in cash and reported an $8.0 million net loss, reflecting decreased R&D and G&A expenses, but lower gains…

Continue Reading

TuesdayNov 12, 2024 8:20 am

BioMedNewsBreaks – Annovis Bio Inc. CEO to Showcase Buntanetap’s Dual Benefits for Alzheimer’s and Parkinson’s at NIA Workshop

Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” Scheduled for Nov. 13, 2024, Dr. Maccecchini’s presentation, titled “One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer’s and Parkinson’s Patients. A Potential Path for Lewy Body Dementia?” will explore the potential of Annovis’s lead drug candidate, Buntanetap, to address neurodegenerative diseases by enhancing cognitive and motor functions, with implications for Lewy body dementia treatment. To view the full press release, visit https://ibn.fm/pOQ1C About…

Continue Reading

MondayNov 11, 2024 9:58 am

BioMedNewsBreaks — Annovis Bio Inc. Advances Alzheimer’s Phase 3 Trials with Strong FDA Support and Financial Backing

Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial to evaluate symptomatic relief and an 18-month trial to assess disease-modifying potential, with the first study slated to start in Q1 2025. Financially, the company raised $12.7 million through its equity line of credit and $7.1 million from warrant exercises, securing its runway to enter Phase 3 trials. Annovis also strengthened…

Continue Reading

MondayNov 11, 2024 8:30 am

BioMedNewsBreaks – HealthLynked Corp. Enhances Oohvie App with Telemedicine and Online Scheduling

HealthLynked (OTCQB: HLYK) has announced a significant update to its Oohvie app, integrating telemedicine services and online scheduling to offer a more comprehensive healthcare experience for women. The update includes a redesigned home screen, enhanced user interface, and expanded functionalities, enabling users to manage their health more effectively through a single platform. CEO Dr. Michael Dent stated that the alignment of Oohvie’s features with the HealthLynked network simplifies personalized, connected care by providing access to telemedicine, appointment scheduling, and secure health data management in one place. To view the full press release, visit https://ibn.fm/C4jIm About HealthLynked Corp. HealthLynked Corp. is committed to…

Continue Reading

FridayNov 08, 2024 10:02 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Advances Toward Commercialization of Cardiac Care Technology with FDA Submissions and Key Leadership Appointments

HeartBeam (NASDAQ: BEAT), reported steady progress in its third quarter financial and operational results, advancing its cardiac care technology through key FDA 510(k) submissions and strategic leadership appointments. The company’s first FDA 510(k) submission for the HeartBeam system is actively under review, with HeartBeam responding to FDA inquiries and preparing for an Early Access Program post-clearance. Following this, HeartBeam plans to submit a second 510(k) application focused on its 12-lead ECG synthesis software. New CEO Robert Eno, along with other senior management hires, aims to guide the company toward U.S. commercialization. HeartBeam has also amassed significant clinical evidence supporting its…

Continue Reading

ThursdayNov 07, 2024 9:59 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Strengthens Clinical Research Team with Appointment of Senior Clinical Scientist

Annovis Bio (NYSE: ANVS) has appointed Dr. Matthew Peterson as Senior Clinical Scientist, bolstering the team as it approaches pivotal Phase 3 trials for its neurodegenerative disease therapies, including treatments for Alzheimer’s and Parkinson’s disease. Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he specialized in therapies for peripheral nerve repair. With expertise in enhancing patient care and research experience with the Department of Veterans Affairs, he will focus on ensuring the scientific rigor and success of Annovis’ clinical trials for its lead drug candidate, buntanetap. To view the…

Continue Reading

MondayNov 04, 2024 10:08 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin’s Potential in Glioblastoma Treatment During KOL Connect Event

CNS Pharmaceuticals (NASDAQ: CNSP), focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, a renowned neuro-oncologist and National Coordinating Investigator for CNS’s study on Berubicin. During the event, Professor Weller discussed the urgent need for effective treatments in glioblastoma multiforme (“GBM”), exploring how Berubicin could serve as a promising therapy within the current limited treatment landscape for this aggressive brain cancer. To view the full press release, visit https://ibn.fm/Qi61Q About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of…

Continue Reading

FridayNov 01, 2024 9:35 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the Nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This extension allows CNS additional time to regain compliance and maintain its listing status. To view the full press release, visit https://ibn.fm/7Kji4 About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and…

Continue Reading

ThursdayOct 31, 2024 9:53 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Spotlight Innovative I&I Pipeline and CDMO Services at BIO-Europe 2024

Scinai Immunotherapeutics (NASDAQ: SCNI) will showcase its inflammation and immunology (“I&I”) product pipeline and contract development and manufacturing (“CDMO”) services at the BIO-Europe 2024 conference in Stockholm from November 4-6. CEO Amir Reichman and CTO Dr. Dalit Weinstein-Fischer will meet with potential clients, pharma partners and investors to discuss co-development opportunities in I&I, collaborations in dermatology, particularly for their Botox-like psoriasis treatment and Scinai’s CDMO capabilities. Scinai will also exhibit at booth #150, where interested parties can learn more about their end-to-end biologics services. To view the full press release, visit https://ibn.fm/oYsuD About Scinai Immunotherapeutics Ltd. Scinai is a biopharmaceutical…

Continue Reading

ThursdayOct 31, 2024 9:15 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 Earnings Call with Key Regulatory and Initiative Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on enhancing cardiac care through advanced insights, will hold a conference call on November 7, 2024, at 4:30 p.m. ET to discuss third-quarter results and share updates on regulatory developments and ongoing projects. CEO Robert Eno, Founder and President Dr. Branislav Vajdic, and CFO Timothy Cruickshank will lead the call, which will include a Q&A session and a presentation accessible via the company’s investor relations page. A press release with detailed Q3 results will be released prior to the call. To view the full press release, visit https://ibn.fm/s1Weu About HeartBeam Inc. HeartBeam…

Continue Reading